

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Persistently increased systemic ACE2 activity and Furin levels are associated with increased inflammatory response in smokers with SARS-CoV-2 COVID-19

Gagandeep Kaur¹, Shaiesh Yogeswaran¹, Thivanka Muthumalage¹,
and Irfan Rahman^{1*}

¹Department of Environmental Medicine, University of Rochester Medical Center,
Rochester, NY

*Correspondence should be addressed to:

Irfan Rahman, Ph.D.
Department of Environmental Medicine
University of Rochester Medical Center
Box 850, 601 Elmwood Avenue
Rochester 14642, NY, USA
Tel: 1 585 275 6911
E-mail: irfan_rahman@urmc.rochester.edu

Short running title: Systemic biomarkers of COVID-19 in smokers

27 **Abstract**

28 **Background:** Tobacco smoking is known to be involved in the pathogenesis of several
29 cardiopulmonary diseases, and smokers are susceptible to infectious agents. However,
30 the progression of lung injury based on COVID-19 susceptibility and severity amongst
31 smokers and those with pre-existing pulmonary diseases is not known. We determined
32 the systemic expression and activity of COVID-19 related proteins, cytokine/chemokines,
33 and lipid mediators (lipidomics) amongst COVID-19 patients with and without a history of
34 smoking with a view to define biomarkers.

35 **Methods:** We obtained serum from COVID-19 positive and COVID-19 recovered patients
36 with and without a history of smoking. We conducted a Luminex multiplex assay (cytokine
37 levels), LC/MS (eicosanoids or oxylipin panel) and enzymatic activity assays on the serum
38 samples to study the systemic changes in COVID-19 patients.

39 **Results:** On comparing the cytokine profiles among COVID-19 positive and COVID-19
40 negative patients, we found a significant upregulation in the production of pro-
41 inflammatory cytokines like IL-1 α , IL-8, IL-2, VEGF and IL-10 in COVID-19 positive
42 patients as compared to the respective controls. Interestingly, smoking history resulted in
43 further augmentation of the release of some hyper-inflammatory cytokines, like IFN- γ ,
44 Eotaxin, MCP-1 and IL-9 amongst COVID-19 positive patients. The enzymatic activity for
45 ACE2, the binding partner for SARS-CoV2 virus in the host cell, was found to be
46 significantly increased in the serum of patients with a smoking history compared to the
47 serum collected from the non-smoking controls. Similarly to our cytokine analysis, our
48 measurement of serum Furin levels was also affected by the patient's smoking history, in
49 which we reported a substantial rise in serum Furin levels of COVID-19 patients. The

50 analysis of lipid mediators revealed a distinct signature amongst the COVID-19 positive
51 versus recovered subjects in $\text{PGF}_{2\alpha}$, HETEs, LXA_4 and LTB_4 levels. However, we did not
52 find any changes in the levels of any lipid mediators based on the smoking history of the
53 patients. Overall, our results point towards distinct systemic signatures amongst COVID-
54 19 positive patients. We also show that smoking adversely affects the systemic levels of
55 inflammatory markers and COVID-19 related proteins, thus suggesting that COVID-19
56 infection may have severe outcomes amongst smokers which is reflected systemically.

57

58 **Keywords:** COVID-19, ACE2, SARS-CoV-2, inflammation, Smoking

59

60

61

62

63

64

65

66

67

68

69

70

71 **Introduction**

72 The current pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major
73 public health threat worldwide. Viral pneumonia and acute respiratory failure are the most
74 common clinical manifestations of severe COVID-19, featuring fever, cough, hypoxemia,
75 dyspnea, and bilateral infiltrates on chest radiography (1). ACE2 (angiotensin converting
76 enzyme 2) receptor is the viral binding site for the SARS-CoV2 in human. ACE2 is
77 abundantly expressed in the lung epithelium, specifically type II pneumocytes, goblet
78 cells, nasal epithelial/ciliated cells and oral mucosal cells (2-4). Under normal
79 circumstances, ACE2 converts angiotensin 2 to metabolites, many of which exert
80 vasodilatory properties. However, since the onset of this pandemic, ACE2 is being widely
81 studied in the context of COVID-19. In this regard, it is still mostly unknown the specific
82 nature of the change in ACE2 induced by SARS-CoV-2 infection, whether it's the
83 modulation of ACE-2 activity or its expression levels that have significance in affecting
84 COVID-19 disease outcome.

85
86 With continual spreading of the virus and reports of a novel, mutant strain causing further
87 alarm and panic, questions regarding COVID19 risk-factors have become even more
88 urgent and a cause for concern. While old age, heart disease and diabetes are the
89 universally accepted risk factors for COVID19, there are many other factors that are
90 subject to debate and require empirical analysis. One such risk factor is smoking. While
91 initial reports on COVID-19 risk factors have indicated little to no risk amongst smokers,
92 recent data suggests otherwise (2, 5). A meta-analysis of 15 studies with a total of 2473
93 confirmed COVID-19 patients reported that COPD patients (63% vs 33.4 in people

94 without COPD) and current smokers (22%) are at a higher risk of severity and mortality
95 due to COVID-19 compared to disease-free and non-smoking individuals respectively
96 (95% confidence interval)(6, 7). Similar findings were reported by Patanavanich et al
97 (2020), whose research suggested that smoking nearly doubles the rate of COVID-19
98 progression amongst patients (8). Despite these findings, the exact pathogenesis of
99 COVID-19 and the clinical features resulting in severe outcomes amongst smokers is
100 largely unexplored.

101
102 In consideration of this lack of research and the growing call of concern for further
103 research into COVID-19 risk-factors, we investigated whether a variation in systemic
104 markers for inflammation and COVID-19 infection existed between smokers and non-
105 smokers. We also studied the gender-based differences in the expression and activity of
106 COVID-19 related proteins (ACE2 and Furin) to understand the progression of the
107 disease amongst both sexes. Evidence from previous literature has suggested
108 upregulated levels of ACE-2 in the lungs of smokers. However, there is no evidence
109 correlating this increased expression to COVID-19 disease development and severity.
110 Our study investigates the relationship between COVID-19 biomarkers and disease
111 severity and shows a marked increase in the inflammatory spillover amongst COVID-19
112 positive patients with a smoking history compared to controls. We were also able to show
113 a pronounced increase in cytokine/chemokine and Furin (S1/S2 cleavage protein) levels
114 in serum of COVID-19 positive patients compared to the COVID-19 recovered controls.
115 Lipid profiling further showed noticeable increases in the levels of Prostaglandin

116 2 α , leukotrienes B₄, lipoxin A₄ and 15- Hydroxyeicosatetraenoic acid in serum collected
117 from COVID-19 positive patients.

118

119 **Materials and Methods**

120 **Ethics/Approval**

121 All the procedures performed in this study comply with the protocols approved by the
122 Institutional Review Board /Research Subject Review Board (RSRB) committee at the
123 University of Rochester Medical Center, Rochester, NY with an approval number
124 CR00002635. The patient samples and information used in this study were procured from
125 a commercial provider- BioIVT (Westbury, NY, USA). All the laboratory procedures were
126 performed in accordance with the regulations specified by the BSL2+ level of containment
127 for Clinical and Research Safety.

128 Human study protocol: Yes; Animal study protocol: None; Institutional biosafety
129 approvals: Yes. The University of Rochester Institutional Biosafety Committee approved
130 the study (study approval number: Rahman/102054/09-167/07-186; identification code:
131 07-186)

132 **Human Blood serum collection**

133 Sera from COVID-19 positive and COVID-19 recovered patients were obtained from
134 BioIVT (Westbury, NY, USA). The patient population was categorized based on smoking
135 status; both current and previous smokers were considered 'Smokers' for subsequent
136 analyses. The characteristics of the study subjects used for the experiments are
137 presented in **Table 1**. In this study, the results obtained from the sera of the COVID-19
138 recovered patient group are considered equivalent to COVID-19 negative patients.

139
140 **Assessment of pro-inflammatory mediators in blood sera using Luminex multiplex**
141 **assay**

142 The levels of pro-inflammatory cytokines/chemokines like MCP-1, IL-8, IFN- γ , TNF- α and
143 IL-7 in the sera were measured by Luminex multiplex assay using Bio-Plex Pro™ Human
144 cytokine 27-plex assay (Cat#M500KCAFOY, BIO-RAD, Hercules, CA) as per
145 manufacturer's directions. Blood plasma was diluted two-folds and the levels of 27 pro-
146 inflammatory mediators (expressed as pg/ml) were measured using Luminex FlexMap3D
147 system (Luminex, Austin, TX).

148 **Assessment of Furin levels using ELISA**

149 To determine the level of Furin in sera collected from COVID-19 positive and negative
150 patients, we employed Human Furin ELISA kit (Cat #: ab113322, Abcam, Cambridge,
151 MA) as per the manufacturer's protocol. Colorimetric detection was performed at 450 nm
152 using Cytation 5 microplate reader (BioTek Instruments, Inc. Winooski, VT). Furin levels
153 were expressed as pg/ml.

154
155 **Assessment of ACE2 Activity**

156 We utilized the ACE2 Activity Assay kit (Cat #: K897 BioVision, Milpitas, CA, USA) to
157 determine the ACE2 activity in the human serum samples. The assay was performed as
158 per the manufacturer's instructions. In brief, serum samples were lysed through the
159 addition of equal volumes of ACE2 Lysis Buffer and ACE2 Assay Buffer. The lysed serum
160 samples, in addition to the appropriate standards and controls (positive, negative, and
161 background), were then added to a 96-well plate. After that, 50 ul of ACE2 substrate was

162 added to both sample and control wells, and subsequently, fluorescence was measured
163 at an excitation maximum of 320 nm and an emission maximum of 420 nm using Cytation
164 5 microplate reader (BioTek Instruments, Inc. Winooski, VT). Total protein content per
165 sample was determined using the Bradford protein assay kit (Thermo Fisher, Waltham,
166 MA). Sample ACE2 activity for each sample was calculated using the following formula:

167
$$\text{Sample ACE2 Activity} = B * D / (\Delta T * P)$$

168 where, B = Released MCA (cleaved product of ACE2 substrate) in Sample based on
169 standard curve slope, ΔT = Reaction time (in min), P = Sample used (in mg), and D =
170 Sample Dilution factor.

171 **Determination of Serum Eicosanoid/Oxylipins levels through Lipidomic Analysis**

172 Serum eicosanoid/oxylipin profiling was outsourced to and performed by Cayman
173 Chemical (Ann Arbor, MI). Lipid profiling was done using ultraperformance liquid
174 chromatography in tandem with mass spectroscopy (UPLC-MS/MS). Lipidomes were
175 prepared using serum from six different patients from each group.

176 **Nomenclature:** The abbreviations used for various classes of lipids include the following:

177 6-keto PGF_{1α}: 6-keto Prostaglandin F_{1α}, TXB₂: Thromboxane B₂, PGF_{2α}: Prostaglandin
178 F_{2α}, PGE₂: Prostaglandin E₂, 12-HHTrE: 12-Hydroxyheptadecatrienoic acid, LTB₄:
179 Leukotriene B₄, LXA₄: Lipoxin A₄, HETE: Hydroxyeicosatetraenoic acid, EET:
180 epoxyeicosatrienoic acid, HODE: Hydroxyoctadecadienoic acid and HDHA: Hydroxy
181 Docosahexaenoic Acid.

182 **Lipid extraction:** Lipid extraction from the serum samples was performed by protein
183 precipitation followed by solid-phase extraction (SPE). Protein precipitation was

184 performed by addition of 50 μ L H₂O: Acetonitrile solution to each sample. Thereafter,
185 SPE was performed using Strata-X cartridges (33 μ m, 200 mg/10 mL; Phenomenex, PA).
186 The extracted lipids were finally dissolved in 100 μ L water/acetonitrile 60:40 (v:v) solution.
187 To prepare the calibration curves, a mixture of the 20 calibration standards was prepared
188 in methanol.

189 **UPLC-MS/MS:** 10 μ L of calibration standards and samples was added to Kinetex (2.6 μ m
190 C18 100 \AA 100x2.1 mm, Phenomenex OOD-4462-AN) column and Reverse phase liquid
191 chromatography (LC) using Sciex ExionLC Integrated System was used for lipid
192 separation. The lipid quantification in the samples was performed using Sciex 6500+. The
193 total amount of eicosanoids present in each sample was determined using MultiQuant
194 software (Sciex). The lipid abundance ratios were calculated in terms of log base 2-fold
195 change and plotted as a heat map.

196 **Statistical Analyses**

197 All statistical calculations were performed using GraphPad Prism 8.0. Data is expressed
198 as mean \pm SE. Pairwise comparisons were done using unpaired Student's *t*-test.
199 Differences were considered statistically significant at **p* < 0.05, ***p* < 0.01, and *** *p* <
200 0.001 when compared with respective controls.

201 **Results**

202 **ACE-2 activity varies as function of smoking history among COVID-19 patients**

203
204
205 Since in humans, ACE2 binds to the SARS-CoV2 spike protein, we investigated changes
206 in COVID-19 positive and COVID-19 negative serum ACE2 activities. To our surprise, we
207 found a significantly higher ACE2 activity in serum from COVID-19 negative patients
208 compared to serum from COVID19 positive patients. (**Fig 1a**). This could have occurred

209 as in this study the COVID-19 negative patient sera actually belong to COVID-19
210 recovered patient group. As expected, after repeating these experiments on blood plasma
211 samples from COVID-19 positive and healthy subjects, we found a significant increase in
212 ACE2 activity in the COVID-19 positive samples compared to healthy controls (data not
213 shown).

214
215 However, it was interesting to find a significant increase in ACE2 activity in serological
216 samples from COVID-19 patients (current and recovered) with a smoking history as
217 compared to non-smokers (**Fig 1b**). In fact, ACE2 activity was found to be more
218 pronounced among male patients compared to females (**Fig 1c**). Our results show that
219 age and smoking status play a crucial role in governing the COVID-19 related enzyme
220 activity in human subjects, thereby affecting the disease pathogenesis amongst
221 individuals.

222
223 **Smoking Upregulates Furin Expression in serological samples from COVID-19**
224 **patients**

225
226 Another key to understanding COVID-19 virulence as a function of susceptibility to viral
227 entry is analyzing changes in Furin levels. Unlike other Coronaviruses, SARS-CoV-2 has
228 a lessened dependence on target host cell proteases and depends more on proprotein
229 convertase Furin for its viral entry. Based on this, we measured Furin-levels in patient
230 sera from COVID-19-positive and COVID-19 negative (COVID-19 recovered) groups
231 using ELISA. We observed a marked increase in the serum Furin levels ($p=0.083$) in

232 COVID-19 positive patients as compared to controls (**Fig 2a**). A significant upregulation
233 of Furin levels was noted among smokers compared to non-smokers among sera
234 collected from COVID-positive (current and previous) patients (**Fig 2b**). Similarly,
235 although not significant, Furin levels among male patients were elevated compared to
236 females; this suggests gender-based variations in the Furin expression on SARS-CoV2
237 infection. (**Fig 2c**).

238

239 **Infection with SARS-CoV-2 upregulates pro-inflammatory cytokine expression in** 240 **smokers**

241

242 It is well known that the exacerbation of the COVID-19 symptoms is associated with an
243 increased expression of pro-inflammatory mediators. Given this, we analyzed the
244 expression of 27 cytokines/chemokines in the serum samples from, COVID-19-positive
245 and COVID-19-negative (recovered) patient population using Luminex multiplex assay.
246 Our results showed significant increases in the levels of IL-8, IL-10, IL-2, VEGF and IL-
247 1α ($p= 0.0616$) in COVID-19 positive patient sera compared to healthy controls (**Fig 3**).
248 Parameters such as, IL-5, GM-CSF, IL-12(p70), and IL-15 were undetected in the patient
249 sera from diseased and normal subjects.

250

251 Intriguingly, when analyzing cytokine/chemokine levels in patient sera based on smoking
252 status, a unique trend emerged. We noted a substantial increase in the production of
253 pro-inflammatory markers like, IFN- γ ($p=0.0836$), MCP-1 and Eotaxin in the COVID-19
254 positive patient sera who had a smoking history compared to the non-smoking controls.

255 Furthermore, we found a moderate increase in the levels of IL-9 ($p=0.0991$) amongst
256 smokers infected with COVID 19 compared to non-smokers (**Fig 4**). These results support
257 our hypothesis and further elucidate the role smoking has in exacerbating both disease
258 severity and outcome with regards to SARS-CoV-2 virulence amongst smokers.

259

260 **Altered serum lipid profile amongst COVID-19 positive patients**

261

262 It is known that infections can induce a variety of alterations in lipid metabolism that
263 could dampen inflammation or fight infection. Thus, we were next interested in studying
264 the changes in the lipid profiles of patient sera from COVID-19 positive and COVID-19
265 negative groups. **Fig 5** depicts a generated heat map which shows alterations in the levels
266 of the 18 most prevalent eicosanoids/oxylipins in sera from COVID-19 positive subjects
267 compared to their respective controls. Most notably, we found noticeable increases in the
268 levels of $PGF_{2\alpha}$, LTB₄, LXA₄, 5HETE, and 20-HETE in COVID-19 positive sera. The
269 detailed account of the fold changes in the levels of each of the studied lipids is provided
270 in **Table 2**.

271

272 **Discussion**

273 The current pandemic of COVID-19 poses a serious threat to the global health and
274 economy. While the efforts of rolling out an effective vaccine are ongoing, there is panic
275 and uncertainty with regards to the new mutant strain of SARS-CoV2 (9). Amidst of this,
276 it is important to recognize the high-risk populations and the underlying differences in the
277 disease pathogenesis to limit the viral spread in an efficient manner. In this regard, we

278 were interested in understanding the COVID-19 disease severity and progression
279 amongst smokers and investigated the systemic responses against SARS-CoV2 infection
280 in COVID-19 positive and COVID-19 negative patients.

281 We first investigated the ACE2 enzyme activity in the patient serum to determine the role
282 of ACE2 in regulating SARS-CoV2 infection. ACE2 is well-known as the binding receptor
283 for the SARS-CoV2 on host's cell surface and use of ACE inhibitors and ARB blockers in
284 COVID-19 patients is being debated since the start of the pandemic. To our surprise, we
285 found an increased ACE2 activity in our COVID-19 negative patients as compared to
286 COVID-19 positive individuals. It is pertinent to mention here that for this study we are
287 denoting COVID-19 recovered patient sera as COVID-19 negative, which could be the
288 reason for this observation. On determining the ACE2 activity in the plasma samples from
289 COVID-19 positive and healthy individuals from a different cohort we observed a
290 significant increase in ACE2 activity in plasma from COVID-19 positive patients as
291 compared to the normal subjects (**Kaur et al., data not shown**). This is an interesting
292 find as it shows that ACE2 activity remains persistently elevated even after recovery and
293 might have important implications for future research. Importantly, ACE2 is expressed in
294 various tissues including the heart, kidney, lungs; and can undergo shedding into the
295 blood circulation. Reports suggest that circulating ACE2 activity is indicative of adverse
296 cardiovascular outcomes in patients with hypertension, coronary artery disease and aortic
297 stenosis (10-12). It is also known to have a negative correlation with the glomerular
298 filtration rate in type 1 diabetes (13, 14). Considering this, our results suggest
299 dysregulated shedding of active ACE2 even after recovery amongst COVID-19 patients
300 which may have adverse effects in the long run and is subject to further investigation.

301 Interestingly, we found that the ACE2 activity was significantly higher for individuals with
302 a smoking history, thus suggesting that smoking can greatly affect the disease severity
303 and outcomes amongst COVID-19 patients. As has been reported previously (15), our
304 data also shows gender-based upregulation of ACE2 activity amongst males as
305 compared to females. This could correlate to the increased morbidity and mortality
306 amongst male patients and must be interesting to study in future.

307

308 We next studied the levels of Furin proteases in the sera of COVID-19 positive and
309 COVID-19 negative patients. Furin enables the cleavage of S-protein thus facilitating viral
310 cell entry into the host (16). Evidence suggests that furin cleavage plays a potent role in
311 the virulence of dengue, HIV and avian flu (17, 18). We observed increased levels of
312 serological Furin in COVID-19 positive patients as compared to controls. We further found
313 that the levels of furin was significantly increased amongst smokers which substantiates
314 our hypothesis that smoking is a risk factor for SARS-CoV2 infection.

315

316 Coinciding with the existing literature (19-21) we also found increased levels of
317 cytokines/chemokines in the patient serum from COVID-19 positive subjects. Additionally,
318 we for the first time, show significant changes in the levels of these pro-inflammatory
319 mediators in COVID-19 positive patients with a smoking history as compared to the non-
320 smoking controls. Upregulation in the factors like IFN- γ , MCP-1 and Eotaxin points
321 towards increased severity of the disease amongst the smokers. Of note, we also found
322 some changes in the lipid profiles of COVID-19 positive and COVID-19 negative patients.
323 Viral infections are known to cause changes in lipid metabolism and play a crucial role in

324 regulating innate and adaptive immune responses. Amongst the lipids that showed
325 marked increase in COVID-19 positive patients were $\text{PGF}_{2\alpha}$, LTB_4 , LXA_4 , 15-HETE and
326 20-HETE. Of these, $\text{PGF}_{2\alpha}$, LTB_4 and 15-HETE are indicative of bronchoconstriction and
327 lung injury (22-24).

328
329 Overall, our results show evidence of inflammatory spill-over in COVID-19 positive
330 patients which is shown to be aggravated in patients who smoke. Pulmonary conditions
331 like COPD and smoking-induced lung injury are known to cause such spillovers into the
332 systemic circulation (25, 26). Thus, it will be important to develop these inflammatory and
333 lipid mediators as biomarkers to ascertain disease severity amongst COVID-19 patients
334 to provide rapid and effective care for better recovery. Though we have not discussed
335 here but vaping population might be yet another population group that may suffer from
336 severe outcomes in event of a SARS-CoV2 infection. Previous work by our group has
337 shown gender-based variation in the ACE2 expression in lung tissues from C57Bl/6J mice
338 exposed to e-cigarette (e-cig) aerosols (27). E-cig use has been associated with loss of
339 lipid homeostasis eventually leading to pulmonary toxicity and lung injury (28, 29). Hence
340 it is important to study the disease progress and pathogenesis in this patient population
341 in smokers and vapers (e-cigarette users) in the future.

342
343 Though we were able to show variations in systemic inflammatory and lipid mediators on
344 SARS-CoV2 infection, our study had some limitations. The sample cohort used for this
345 study was relatively smaller and comprised of a relatively homogenous demographics. It
346 is important to conduct these experiments on a larger sample population with a

347 heterogeneous demographics to deduce better conclusions. Also, we intend to use
348 patient serum from healthy or COVID-19 negative individuals in the future to compare the
349 variations amongst COVID-19 positive, recovered and healthy subjects. The persistently
350 elevated ACE2 activity in the COVID-19 recovered patients provides evidence for a much
351 thorough investigation into the long-term health effects of SARS-CoV2 infection in
352 smokers. Such an exploration is crucial to understand the mechanistic role of intact and
353 circulating ACE2 in COVID-19 and deduce if recombinant ACE2 could develop as a
354 therapy.

355
356 In conclusion, we show that the systemic ACE2 activity, Furin levels and cytokine release
357 is upregulated amongst COVID-19 patients with a smoking history, thereby rendering
358 them more susceptible to severe symptoms and disease outcomes. We also show that
359 smoking adversely affects the systemic levels of inflammatory markers and COVID-19
360 related proteins, thus suggesting that COVID-19 infection may have severe outcomes
361 amongst smokers which is reflected systemically. We also provide evidence for
362 inflammatory systemic spillover due to COVID-19 which could be crucial in identifying
363 biomarkers or developing future therapies, and/or monitoring therapies in susceptible
364 population.

365

366 **List of Abbreviations**

367 COVID-19: Coronavirus Disease-2019

368

369 ACE2: Angiotensin converting Enzyme 2

370

371 GM-CSF: Granulocyte-macrophage Colony stimulating Factor

372

373 HIV: Human Immunodeficiency Virus

374

375 COPD: Chronic obstructive pulmonary disease

376

377

378 **Acknowledgements:** We thank Dr. Shikha Sharma for technical assistance.

379 **Declarations:** The authors have declared that no competing interests exist.

380 **Author's Contribution:** GK, and SY designed and conducted the experiments, GS,

381 SY, and IR wrote and edited/revised the manuscript. TM analyzed the lipidomic data and

382 edited the manuscript. IR obtained research funding and conceptually designed the

383 overall manuscript.

384

385 **References**

- 386 1. Brosnahan SB, Jonkman AH, Kugler MC, Munger JS, Kaufman DA. COVID-19 and
387 Respiratory System Disorders: Current Knowledge, Future Clinical and Translational Research
388 Questions. *Arteriosclerosis, thrombosis, and vascular biology*. 2020;40(11):2586-97.
- 389 2. Kaur G, Lungarella G, Rahman I. SARS-CoV-2 COVID-19 susceptibility and lung
390 inflammatory storm by smoking and vaping. *Journal of inflammation (London, England)*.
391 2020;17:21.
- 392 3. Ziegler CGK, Allon SJ, Nyquist SK, Mbanjo IM, Miao VN, Tzouanas CN, et al. SARS-
393 CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is
394 Detected in Specific Cell Subsets across Tissues. *Cell*. 2020;181(5):1016-35.e19.
- 395 4. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2
396 entry factors are highly expressed in nasal epithelial cells together with innate immune genes.
397 *Nature medicine*. 2020;26(5):681-7.
- 398 5. Grundy EJ, Suddek T, Filippidis FT, Majeed A, Coronini-Cronberg S. Smoking, SARS-
399 CoV-2 and COVID-19: A review of reviews considering implications for public health policy and
400 practice. *Tobacco induced diseases*. 2020;18:58.
- 401 6. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almeahmadi M, Alqahtani AS, et al.
402 Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-
403 19: A Rapid Systematic Review and Meta-Analysis. *PLoS One*. 2020;15(5):e0233147-e.
- 404 7. Leung JM, Sin DD. Smoking, ACE-2 and COVID-19: ongoing controversies. *The*
405 *European respiratory journal*. 2020;56(1).
- 406 8. Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A
407 Meta-analysis. *Nicotine & tobacco research : official journal of the Society for Research on*
408 *Nicotine and Tobacco*. 2020;22(9):1653-6.
- 409 9. Baric RS. Emergence of a Highly Fit SARS-CoV-2 Variant. 2020;383(27):2684-6.
- 410 10. Ramchand J, Burrell LM. Circulating ACE2: a novel biomarker of cardiovascular risk.
411 *Lancet (London, England)*. 2020;396(10256):937-9.

- 412 11. Úri K, Fagyas M, Kertész A, Borbély A, Jenei C, Bene O, et al. Circulating ACE2 activity
413 correlates with cardiovascular disease development. *Journal of the renin-angiotensin-*
414 *aldosterone system : JRAAS*. 2016;17(4).
- 415 12. Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasma
416 angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac
417 events in patients with obstructive coronary artery disease. *PLoS One*. 2018;13(6):e0198144-e.
418 13. Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, et
419 al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular
420 complications. *Journal of hypertension*. 2012;30(2):375-83.
- 421 14. Anguiano L, Riera M, Pascual J, Valdivielso JM, Barrios C, Betriu A, et al. Circulating
422 angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with
423 chronic kidney disease. *Atherosclerosis*. 2016;253:135-43.
- 424 15. Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, et al.
425 Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with
426 heart failure and effects of renin-angiotensin-aldosterone inhibitors. *European heart journal*.
427 2020;41(19):1810-7.
- 428 16. Xia S, Lan Q, Su S, Wang X, Xu W, Liu Z, et al. The role of furin cleavage site in SARS-
429 CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. *Signal*
430 *transduction and targeted therapy*. 2020;5(1):92.
- 431 17. Fitzgerald K. Furin Protease: From SARS CoV-2 to Anthrax, Diabetes, and
432 Hypertension. *The Permanente journal*. 2020;24.
- 433 18. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function,
434 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 2020;181(2):281-92.e6.
- 435 19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
436 with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*.
437 2020;395(10223):497-506.
- 438 20. Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine
439 Release Syndrome. *Immunity*. 2020;52(5):731-3.
- 440 21. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine
441 storm: The anger of inflammation. *Cytokine*. 2020;133:155151.
- 442 22. Fish JE, Jameson LS, Albright A, Norman PS. Modulation of the bronchomotor effects of
443 chemical mediators by prostaglandin F2 alpha in asthmatic subjects. *The American review of*
444 *respiratory disease*. 1984;130(4):571-4.
- 445 23. Martin TR, Pistorese BP, Chi EY, Goodman RB, Matthay MA. Effects of leukotriene B4
446 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in
447 protein permeability. *The Journal of clinical investigation*. 1989;84(5):1609-19.
- 448 24. Zhu D, Medhora M, Campbell WB, Spitzbarth N, Baker JE, Jacobs ER. Chronic hypoxia
449 activates lung 15-lipoxygenase, which catalyzes production of 15-HETE and enhances
450 constriction in neonatal rabbit pulmonary arteries. *Circulation research*. 2003;92(9):992-1000.
- 451 25. Liu YY, Chiang CH, Chuang CH, Liu SL, Jheng YH, Ryu JH. Spillover of cytokines and
452 reactive oxygen species in ventilator-induced lung injury associated with inflammation and
453 apoptosis in distal organs. *Respiratory care*. 2014;59(9):1422-32.
- 454 26. Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may
455 adipose tissue play a role? Review of the literature and future perspectives. *Mediators of*
456 *inflammation*. 2010;2010:585989.
- 457 27. Wang Q, Sundar IK, Li D, Lucas JH, Muthumalage T, McDonough SR, et al. E-cigarette-
458 induced pulmonary inflammation and dysregulated repair are mediated by nAChR $\alpha 7$ receptor:
459 role of nAChR $\alpha 7$ in SARS-CoV-2 Covid-19 ACE2 receptor regulation. *Respiratory research*.
460 2020;21(1):154.

- 461 28. Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, et al. Electronic
462 cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. The
463 Journal of clinical investigation. 2019;129(10):4290-304.
464 29. Chand HS, Muthumalage T, Maziak W, Rahman I. Pulmonary Toxicity and the
465 Pathophysiology of Electronic Cigarette, or Vaping Product, Use Associated Lung Injury. Front
466 Pharmacol. 2020;10:1619-.

467
468

469 **Tables**

470 **Table 1: Characteristics of COVID-19 positive and negative subjects**

Characteristics	COVID-19 negative patients	COVID-19 positive patients
N	21	16
Age (years), mean (SD)	46.71 (13.44)	39.75 (14.68)
Smoker, n (%)	7 (33.33)	3 (18.75)

471
472
473
474
475
476
477
478
479
480
481

482

483

484

485

486

487

488

489


490

491 **Table 2: Differentially altered lipid analytes in COVID-19 positive patient sera with**
492 **respective fold changes**
493

Analyte	Log2 fold change (Cov+ vs CoV-)	SD
6-keto PGF _{1a}	0.078348	0.483034
TXB ₂	-0.35068	2.271691
PGF _{2a}	0.854693	0.877836
PGE ₂	0.685295	1.65742
12-HHTrE	-0.56546	1.837558
LTB ₄	1.31646	1.100475
LXA ₄	0.112419	1.132973
5-HETE	1.446217	1.704243
11-HETE	0.948088	1.31254
12-HETE	0.473277	0.935641
15-HETE	0.808158	1.10055
20-HETE	0.687371	0.892525
5(6)-EET	1.123827	0.756739
8(9)-EET	-0.15191	3.07822
11(12)-EET	0.714846	1.34743
9-HODE	-0.83099	1.994469
13-HODE	-0.61875	1.361414
17-HDHA	-0.7935	1.346715


514

Figure 1



515
516 **Figure 1: Increased ACE2 activity amongst COVID-19 patients with a smoking**
517 **history.** Patient Sera from COVID-19 positive and COVID-19 negative (COVID19
518 recovered) subjects was obtained and the ACE2 activity was quantitatively measured.
519 The obtained results were plotted based on serum Furin levels in (a) COVID-19 negative
520 (COVID-19 recovered) vs COVID-19 positive patients, (b) COVID-19 positive (current or
521 previous) patients with or without a smoking history, and (c) COVID-19 patients based on
522 their gender . Data are shown as mean \pm SEM (n = 8–15/group). *p<0.05, *** p<0.0001
523 as per Student's t-test for pairwise comparisons. CoV-: COVID-19 negative (COVID-19
524 Recovered), CoV+: COVID-19 positive patients.
525

Figure 2




526

527 **Figure 2: Increased Furin levels amongst COVID-19 patients with a smoking**
528 **history.**


529 Blood serum from COVID-19 positive and COVID-19 negative (COVID-19 recovered)
530 patients were obtained and the Furin levels were quantitatively measured. The obtained
531 results were plotted based on serum Furin levels in (a) COVID-19 negative vs COVID-19
532 positive (COVID-19 recovered) patients, (b) COVID-19 positive patients (current or
533 previous) patients with or without a smoking history, and (c) COVID-19 patients based on
534 their gender . Data are shown as mean \pm SEM (n = 8–15/group). ** $p < 0.001$ as per
535 Student's t-test for pairwise comparisons. CoV-: COVID-19 negative (COVID-19
536 Recovered), CoV+: COVID-19 positive patients

Figure 3




537
538 **Figure 3: Elevated cytokine levels in COVID-19 positive patients.** Blood serum
539 samples from COVID-19 positive, and COVID-19 negative (COVID-19 recovered)
540 patients were collected and the levels of cytokines/chemokines was assessed with the
541 help of Luminex multiplex assay. The levels of detected cytokines was plotted using
542 GraphPad Prism 8. Data are shown as mean \pm SEM (n = 10-15/group). * p<0.05, **
543 p<0.01; vs CoV- patients as per One-way ANOVA for multiple comparisons. CoV-:
544 COVID-19 negative (COVID-19 recovered), CoV+: COVID-19 positive patients.
545 Cytokines not detected IL-5, GM-CSF, IL-12(p70) and IL-15

Figure 4



546
 547 **Figure 4: Hyperinflammation in COVID-19 positive patients with a smoking history.**
 548 Levels of cytokines/chemokines as assessed with the help of Luminex multiplex assay in
 549 blood serum samples from COVID-19 positive patients with and without a smoking history
 550 (NS: non-smokers and smokers) were collected (n = 3–10/group). Data are shown as
 551 mean ± SEM. *p<0.05, as per Student's t-test for pairwise comparisons.

Figure 5



552

553 **Figure 5: Heat map of eicosanoid levels in COVID-19 positive and COVID-19**
554 **negative patient serum.** The fold changes in the eicosanoid levels in COVID-19 negative
555 (COVID-19 recovered) patient serum as compared to COVID-19 positive serum. Each
556 horizontal row represents the analyte in a specific lipid class and each vertical column
557 represents the individual sample being tested. Lipid abundance ratios are colored
558 according to the fold changes and the color key indicates the magnitude of log₂ fold
559 change.
560